[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"primary-aldosteronism\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:primary-aldosteronism":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,47,0,25,[9,44,68,92,117,142,171,192,213,237,256,277,304,331,351,373,398,422,442,470,490,520,548,576,598],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100644745","intensive-vs-standard-blood-pressure-control-in-primary-aldosteronism-100644745",false,"NCT07673445","Intensive vs. Standard Blood Pressure Control in Primary Aldosteronism","Intensive Versus Standard Blood Pressure Control in Patients With Primary Aldosteronism (Intensia-Aldo): A Multi-center, Randomized Controlled Trial","Intensia-Aldo","Inclusion Criteria:\n\nParticipants must meet all of the following criteria to be eligible for enrollment:\n\n1. A diagnosis of PA meeting the following criteria: an upright plasma aldosterone-to-renin ratio (ARR) ≥20 (pg\u002FmL)\u002F(μIU\u002FmL) or ≥300 (pg\u002FmL)\u002F(ng\u002FmL\u002Fh); and at least one positive confirmatory test: plasma aldosterone ≥110 pg\u002FmL after the captopril challenge test (CCT) or plasma aldosterone ≥80 pg\u002FmL after the seated saline infusion test (SSIT).\n\n   Note: For patients with an upright ARR ratio between 10-20 (pg\u002FmL)\u002F(μIU\u002FmL), the screening result can also be considered positive if they have additional high-risk factors such as adrenal lesions or resistant hypertension. Patients receiving medications that may suppress renin and lead to false-positive results (e.g., β-adrenergic blockers and centrally acting α₂-agonists such as clonidine or α-methyldopa) should discontinue these medications and repeat testing after a 2-week washout period.\n2. Systolic blood pressure of 140-190 mmHg (or currently receiving antihypertensive treatment).\n\n   Notes: (1) Office mean seated blood pressure is defined as the average of three seated blood pressure measurements obtained at any single on-site visit. (2) There is no diastolic blood pressure criterion for inclusion.\n3. Increased risk of cardiovascular disease (one or more of the following):\n\n   * Previous history of clinical CVD (≥ 3 months)\n\n     * Stroke\n     * Myocardial infarction\n     * Percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)\n     * Carotid endarterectomy or carotid stenting\n     * Peripheral artery disease (PAD) with revascularization\n     * Acute coronary syndrome with or without resting ECG change, ECG changes on a graded exercise test, or positive cardiac imaging study\n   * Subclinical CVD within 3 years\n\n     * ≥50% stenosis of a coronary, carotid, or lower extremity artery\n     * Ankle brachial index (ABI) ≤0.90\n     * Chest pain with evidence of myocardial ischemia\n   * 2 or more CVD risk factors\n\n     * Male ≥50 years or female ≥55 years\n     * History of smoking (≥1 cigarette per day in the past 12 months)\n     * Diabetes mellitus\n     * BMI \\>28 kg\u002Fm²\n     * Dyslipidemia despite receiving maximally tolerated statin therapy: LDL cholesterol \\>130 mg\u002FdL (\\>3.36 mmol\u002FL), or HDL cholesterol \\\u003C40 mg\u002FdL (\\\u003C1.03 mmol\u002FL) in males or \\\u003C50 mg\u002FdL (\\\u003C1.29 mmol\u002FL) in females\n     * Family history of premature coronary heart disease (defined as myocardial infarction or coronary revascularization) in a first-degree relative: male relative \\\u003C55 years or female relative \\\u003C65 years\n     * Microalbuminuria (Note: If microalbuminuria is the only criterion, a repeat test is required for confirmation)\n   * Estimated glomerular filtration rate (eGFR) 30-59 ml\u002Fmin\u002F1.73 m²\n\nExclusion Criteria:\n\n1. Patients with PA who are planned to undergo adrenal surgical treatment.\n2. Other clearly diagnosed forms of secondary hypertension (excluding subclinical Cushing's syndrome and obstructive sleep apnea \\[OSA\\]).\n3. Severe hypertension: systolic blood pressure (SBP) ≥190 mmHg or diastolic blood pressure (DBP) ≥110 mmHg.\n4. Diastolic blood pressure \\\u003C60 mmHg (without antihypertensive medication).\n5. Myocardial infarction, unstable angina, stroke, or coronary revascularization (PCI or CABG) within the past 3 months.\n6. Planned coronary revascularization (PCI or CABG) within the next 6 months.\n7. Severe valvular heart disease, or valvular disease likely to require surgical or percutaneous valve replacement during the study period.\n8. Hypertrophic cardiomyopathy (HCM). Definition: A disease characterized by unexplained left ventricular hypertrophy, with a non-dilated ventricular cavity and absence of other cardiac or systemic diseases. Clinically, HCM is usually diagnosed by echocardiography, defined as a maximum left ventricular wall thickness ≥15 mm, or 13-14 mm (considered borderline), particularly in the presence of additional supporting evidence (e.g., a family history of HCM). In elderly patients with left ventricular hypertrophy and a long-standing history of systemic hypertension, a diagnosis of HCM may be established if a definite sarcomeric gene mutation is identified, or if left ventricular wall thickness is markedly \\>25 mm and\u002For there is left ventricular outflow tract obstruction with systolic anterior motion of the mitral valve and mitral valve-septal contact.\n9. NYHA functional class III-IV heart failure or left ventricular ejection fraction \\\u003C35%.\n10. ALT or AST \\>2.5 times the upper limit of normal, or active liver disease.\n11. Dialysis dependence or eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m².\n12. Polycystic kidney disease or glomerulonephritis.\n13. Any condition with an expected life expectancy \\\u003C5 years.\n14. Factors likely to affect adherence to the intervention, including:\n\n    * Alcohol abuse or drug abuse within the past 12 months.\n    * History of severe non-adherence to medication or follow-up.\n    * Residence far from the study center or planned relocation within 5 years.\n    * Clinical diagnosis or treatment of dementia, or cognitive impairment preventing adherence to the protocol.\n    * Other medical, psychiatric, or behavioral factors that may interfere with study participation.\n15. Failure to provide written informed consent.\n16. Current participation in another interventional study.\n17. Pregnancy, planned pregnancy, or women of childbearing potential not using effective contraception.","ALL",{"count":20,"type":21},3830,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to evaluate whether an intensive blood pressure control strategy (systolic blood pressure target \\\u003C120 mmHg) is more effective than a standard strategy (systolic blood pressure target \\\u003C140 mmHg) in reducing the risk of cardiovascular events in patients with primary aldosteronism.\n\nThe main question it aims to answer is: Does the intensive blood pressure control strategy reduce the risk of composite cardiovascular events more than the standard strategy in patients with primary aldosteronism? The study employs a randomized design, allocating participants in a 1:1 ratio to either the Intensive Treatment Group or the Standard Treatment Group. Researchers will compare the differences in cardiovascular outcomes and safety profiles between the two groups over a planned follow-up period of 6 to 10 years.\n\nParticipants will:\n\nUndergo randomization and adhere to the assigned blood pressure management protocol.\n\nAttend regular follow-up visits for blood pressure measurement, laboratory tests, questionnaires, etc.\n\nReport any adverse events or changes in health status.",[27],"Primary Aldosteronism",[29,30],"treatment","intensive blood pressure control","NOT_YET_RECRUITING","2026-06-23",{"date":34,"type":35},"2026-06-29","ACTUAL",{"date":37,"type":21},"2026-06",{"date":39,"type":21},"2036-12",{"name":41,"class":42},"Chongqing Medical University","OTHER",1,{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":18,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":43},"100498094","diagnosing-variable-primary-aldosteronism-100498094","NCT05765786","Diagnosing Variable Primary Aldosteronism.","Do we Miss a Common Subset of Primary Aldosteronism in Which There is Cyclical or Exaggerated Diurnal Variation in Secretion?","Inclusion Criteria:\n\n* People with clinically suspected PA but have not met criteria for diagnosis. Suspicion based on low-renin (renin activity \\\u003C0.5 nmol\u002Fh\u002FL or renin mass \\\u003C5 ng\u002FL), plasma sodium \\> 140mmol\u002FL or plasma potassium \\\u003C 4mmol\u002FL.\n* Patients who have been diagnosed with PA and had previous aldosterone samples \\\u003C277 pmol\u002FL, a level which would normally not qualify for confirmatory testing.\n* Patients with aldosterone results done at different times that indicate variability in production.\n* Willing to consent and participate in the study.\n\nExclusion Criteria:\n\n* Inability to withdraw β-adrenoceptor antagonist therapy for 2 weeks.\n* People on end of life treatment.","18 Years",{"count":53,"type":21},100,"OBSERVATIONAL","The goal of this observational study is to see if there is a cyclical or exaggerated diurnal variation in aldosterone production in people with Primary Aldosteronism.",[27,57],"High Blood Pressure","RECRUITING","2026-06-12",{"date":61,"type":35},"2026-06-15",{"date":63,"type":35},"2023-02-24",{"date":65,"type":21},"2027-07-24",{"name":67,"class":42},"Queen Mary University of London",{"id":69,"slug":70,"hasResults":12,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":12,"sex":18,"minAge":51,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":79,"conditions":80,"keywords":81,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":86,"completionDateStruct":87,"leadSponsor":89,"locationsCount":43},"100642963","phase-2-a-phase-ii-clinical-trial-of-efficacy-and-safety-of-sal0140-at-different-doses-in-patients-with-primary-aldosteronism-100642963","NCT07646535","A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Primary Aldosteronism","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Primary Aldosteronism","Inclusion Criteria:\n\n1. Aged ≥18 years , regardless of gender.\n2. Diagnosed with primary aldosteronism (PA).\n3. Mean seated office systolic blood pressure (msSBP) ≥145 mmHg.\n4. Receiving stable background antihypertensive therapy.\n5. Serum potassium tested at local laboratory ≥3.0 mmol\u002FL and \\\u003C5.0 mmol\u002FL.\n6. Morning serum cortisol \\>3 μg\u002FdL.\n7. Voluntarily participate in the trial and provide written informed consent. Agree to comply with trial contraception and reproductive restrictions.\n\nExclusion Criteria:\n\n1. Mean seated office systolic blood pressure (msSBP) ≥180 mmHg and\u002For mean seated office diastolic blood pressure (msDBP) ≥110 mmHg.\n2. History or diagnosis of malignant hypertension, hypertensive emergency, hypertensive crisis or hypertensive encephalopathy.\n3. History or diagnostic evidence of other secondary hypertension.\n4. Prior surgical resection for adrenal adenoma.\n5. Medication compliance \\\u003C80% or \\>120%.\n6. PA complicated with acute coronary syndrome, myocardial infarction, percutaneous coronary intervention or stroke.\n7. Receiving treatment with potassium-binding agents.\n8. Any clinically significant abnormal laboratory findings that, in the Investigator's opinion, may interfere with the evaluation of efficacy and\u002For safety endpoints of the study.\n9. Subjects with severe hepatobiliary diseases.\n10. Positive test for human immunodeficiency virus antibody (HIV), hepatitis C antibody (HCV), treponema pallidum antibody (TP), or positive hepatitis B surface antigen (HBsAg).\n11. Type 1 diabetes mellitus or poorly controlled type 2 diabetes mellitus.\n12. Morbid obesity.\n13. Receiving blood transfusion for anemia.\n14. History of adrenal insufficiency.\n15. History of solid organ or bone marrow transplantation.\n16. Prior exposure to rituximab or cytotoxic chemotherapeutic agents.\n17. Recent use of strong CYP3A inhibitors or CYP3A inducers.\n18. Concomitant use of antihypertensive drugs, or other chemical drugs, biological products, traditional Chinese medicines or natural products deemed inappropriate by the Investigator.\n19. Active malignancy or past medical history of malignant tumor.\n20. Patients on hemodialysis or strict salt-restricted diet.\n21. Gastrointestinal disorders or prior gastrointestinal surgery that may affect drug absorption or excretion.\n22. Known or suspected hypersensitivity to aldosterone synthase inhibitors; known contraindication or hypersensitivity to any background concomitant medications.\n23. History of substance abuse or chronic alcohol abuse.\n24. Female subjects who are pregnant, breastfeeding, or with positive pregnancy test result.\n25. Recent blood donation or major blood loss (\\>400 mL), or clinically diagnosed hypovolemia.\n26. Participation in any interventional clinical trial with investigational product within 3 months prior to screening (or within 5 half-lives of the investigational product, whichever is longer); or enrollment in any medical device clinical trial with implanted\u002Fused study device.\n27. Night shift work within 3 days prior to study visit and within 3 days before ambulatory blood pressure monitoring.\n28. Presence of clinically significant, unstable or uncontrolled concomitant diseases as assessed by the Investigator at screening.\n29. Any other conditions judged by the Investigator to render the subject unsuitable for trial participation and likely to confound efficacy and\u002For safety assessment.",{"count":76,"type":21},50,[78],"PHASE2","This is a multicenter, randomized, double-blind, placebo-controlled phase II study designed to explore the efficacy and safety of different doses of SAL0140 in primary aldosteronism.",[27],[27,82,83],"Aldosterone Synthase Inhibitor","Renin","2026-06-08",{"date":59,"type":35},{"date":59,"type":21},{"date":88,"type":21},"2027-12-31",{"name":90,"class":91},"Shenzhen Salubris Pharmaceuticals Co., Ltd.","INDUSTRY",{"id":93,"slug":94,"hasResults":12,"nctId":95,"briefTitle":96,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":98,"sex":18,"minAge":51,"maxAge":99,"enrollmentInfo":100,"targetDuration":102,"studyType":54,"phases":4,"briefSummary":103,"conditions":104,"keywords":105,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":43},"100643441","study-on-the-diagnostic-cut-off-point-of-24-hour-urinary-aldosterone-measured-by-liquid-chromatography-tandem-mass-spectrometry-in-the-diagnosis-of-primary-aldosteronism-in-the-oral-sodium-loading-test-100643441","NCT07635134","Study on the Diagnostic Cut-off Point of 24-hour Urinary Aldosterone Measured by Liquid Chromatography-Tandem Mass Spectrometry in the Diagnosis of Primary Aldosteronism in the Oral Sodium Loading Test","Inclusion criteria for the normal control group: Age 18-70 years old, BMI: 18.5-23.9kg\u002Fm ²，gender not restricted. blood pressure: 100-120\u002F60-80mmHg. no history of hypertension. No abnormal nodules found in adrenal CT. Previous blood potassium and electrocardiogram were all within normal ranges., No history of liver or kidney dysfunction, malignant tumors, metabolic diseases or cardiovascular diseases, and no medication used.\n\nExclusion criteria: Those with a family history of hypertension or with clinical manifestations of secondary hypertension. Those who have been taking drugs that may affect the RAAS system for a long time (such as contraceptives, steroids, etc.). Those with cardiac dysfunction or severe arrhythmia and unable to tolerate the test.\n\nPatients with suspected primary aldosteronism in the outpatient setting. Inclusion criteria: Patients with suspected primary aldosteronism in the outpatient setting. Willing to undergo 4-week spironolactone treatment and cooperate with follow-up.\n\nExclusion criteria: Patients who did not complete the oral sodium loading test. Patients with Cushing's syndrome or other endocrine tumors. Patients allergic to spironolactone or with contraindications for its use (such as severe hyperkalemia, eGFR \\\u003C 30).History of liver or kidney dysfunction, coexisting severe cardiovascular or cerebrovascular diseases, history of malignant tumors, other types of endocrine hypertension (hyperthyroidism, pheochromocytoma, Cushing's syndrome, etc.), renal artery stenosis, hypokalemia caused by other factors (renal tubular acidosis, Bartter syndrome, Gitelman syndrome, etc.), diabetes with HbA1c \\> 7.0% or currently using or having used insulin or SGLT2 inhibitor drugs, taking special medications such as glucocorticoids, immunosuppressants, oral contraceptives, etc.",true,"70 Years",{"count":101,"type":21},800,"6 Months","Primary aldosteronism (PA) is the most common cause of secondary hypertension. Liquid chromatography - tandem mass spectrometry (LC-MS\u002FMS) is more accurate than the traditional radioimmunoassay in measuring aldosterone. This study aims to establish a more precise diagnostic threshold for the oral sodium loading test (OSLT) by using LC-MS\u002FMS to measure urinary aldosterone levels. We will combine the biochemical results of OSLT and other data from healthy volunteers and suspected PA patients to determine a new 24-hour urinary aldosterone threshold. We expect to improve the diagnostic accuracy of PA, helping clinicians identify this curable cause of hypertension earlier and more accurately, and achieving precise treatment.",[27],[106,107],"the oral sodium loading test","diagnose","2026-06-03",{"date":110,"type":35},"2026-06-09",{"date":112,"type":35},"2025-04-01",{"date":114,"type":21},"2026-08-01",{"name":116,"class":42},"Peking Union Medical College Hospital",{"id":118,"slug":119,"hasResults":12,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":12,"sex":18,"minAge":51,"maxAge":4,"enrollmentInfo":125,"targetDuration":127,"studyType":54,"phases":4,"briefSummary":128,"conditions":129,"keywords":130,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":140,"locationsCount":43},"100639397","study-on-cutoff-revision-effects-and-evaluation-of-nnt-in-primary-aldosteronism-100639397","NCT07621458","Study on Cutoff Revision Effects and Evaluation of NNT in Primary Aldosteronism","Impact of the Revised Aldosterone-Renin Ratio (ARR) Cutoff in the 2025 Primary Aldosteronism Guideline in Real-World Practice: A Prospective Study","SCREEN-PA","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Diagnosis of hypertension or current use of antihypertensive medications\n* Plasma renin activity (PRA) ≤1 ng\u002FmL\u002Fhr\n* Plasma aldosterone concentration (PAC) ≥10 ng\u002FdL by immunoassay or ≥7.5 ng\u002FdL by liquid chromatography-tandem mass spectrometry (LC-MS\u002FMS)\n* Aldosterone-to-renin ratio (ARR) \\>20 by immunoassay or \\>15 by LC-MS\u002FMS\n* Participants meeting criteria for intermediate probability of lateralizing primary aldosteronism\n* For participants with ARR values between 20 and 30, repeat ARR measurement within 26 weeks demonstrating persistent ARR \\>20\n\nExclusion Criteria:\n\n* Current use of mineralocorticoid receptor antagonists or amiloride that cannot be discontinued according to study protocol\n* Previous adrenalectomy\n* Chronic kidney disease stage 4 or higher (estimated glomerular filtration rate \\\u003C30 mL\u002Fmin\u002F1.73 m²)\n* Pregnancy\n* Current use of combined estrogen- and progesterone-containing oral contraceptive pills or hormone replacement therapy\n* High probability primary aldosteronism defined as hypokalemia with PRA \\\u003C0.2 ng\u002FmL\u002Fhr and PAC \\>20 ng\u002FdL by immunoassay or \\>15 ng\u002FdL by LC-MS\u002FMS\n* Low probability primary aldosteronism defined as PAC \\\u003C11 ng\u002FdL by immunoassay or \\\u003C8 ng\u002FdL by LC-MS\u002FMS\n* Inability to undergo saline infusion test according to investigator judgment",{"count":126,"type":21},150,"1 Year","The goal of this observational study is to evaluate the real-world impact of applying the revised aldosterone-to-renin ratio (ARR) cutoff recommended in the 2025 primary aldosteronism guideline in adults with hypertension and biochemical findings suggestive of an intermediate probability of lateralizing primary aldosteronism (PA). The main questions it aims to answer are:\n\n* What is the number needed to test (NNT) to diagnose one case of primary aldosteronism when using the revised ARR cutoff (\\>20)?\n* What is the optimal ARR cutoff for diagnosing PA in Korean patients?\n* What is the biochemical treatment response rate at 6 months after treatment for confirmed PA?\n\nParticipants will:\n\n* Undergo standardized ARR testing after protocol-based medication adjustment and controlled sampling conditions.\n* Undergo confirmatory testing using the saline infusion test (SIT).\n* Receive standard clinical management for confirmed PA according to institutional practice.\n* Be followed for assessment of biochemical outcomes after treatment.",[27],[27,131,132,133],"Aldosterone-to-Renin Ratio","Number Needed to Test","Screening","2026-05-31",{"date":136,"type":35},"2026-06-02",{"date":138,"type":35},"2026-04-01",{"date":88,"type":21},{"name":141,"class":42},"Seoul National University Hospital",{"id":143,"slug":144,"hasResults":12,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":12,"sex":18,"minAge":51,"maxAge":149,"enrollmentInfo":150,"targetDuration":4,"studyType":22,"phases":152,"briefSummary":153,"conditions":154,"keywords":157,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":43},"100467540","endoscopic-ultrasound-guided-radiofrequency-ablation-in-primary-aldosteronism-100467540","NCT05368090","Endoscopic Ultrasound-guided Radiofrequency Ablation in Primary Aldosteronism","Endoscopic Ultrasound-guided Radiofrequency Ablation as a Novel Treatment Option Compared With Adrenalectomy in Left-sided Primary Aldosteronism","Inclusion Criteria all groups\n\n* Signed written informed consent\n* If CT scan shows an adrenal nodule to the same adrenal as AVS lateralisation result: nodule size \\\u003C 4 cm and enhancement criteria for adrenal adenoma (native hounsfield units \\\u003C 10 or relative wash-out \\> 40% or absolute wash-out \\> 60%)\n\nPA unilateral group inclusion criteria:\n\n* Age 18 to 60 years\n* PA diagnosis confirmed according to Endocrine Society PA Guideline criteria\n* AVS lateralisation to left adrenal (lateralisation index ≥ 4,0)\n\nPA \"debulking\" group inclusion criteria:\n\n* Age 18 to 70 years\n* PA diagnosis confirmed according to Endocrine Society PA Guideline criteria\n\nMACS unilateral and debulking group inclusion criteria:\n\n* Age 18 to 80 years\n* MACS diagnosis confirmed according to ENSAT\u002FECE Guideline criteria\n* AVS lateralisation to the left adrenal, and visible left adrenal tumor on CT scan OR bilateral overproduction of cortisol on AVS, and bilateral tumors\u002Fhyperplasia on CT scan (debulking)\n\nExclusion Criteria all groups:\n\n* CT scan suspicion of adrenal malignancy\n* Patient refusal to undergo either EUS-RFA or adrenalectomy","80 Years",{"count":151,"type":21},60,[24],"In this study, the investigators will perform endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) treatment of left-sided adrenal tumours in patients with primary aldosteronism (PA) and in patients with mild autonomous cortisol secretion (MACS). Four different study groups will all receive EUS-RFA of left-sided adrenal tumours. Clinical and biochemical outcome as well as procedural safety will be evaluated. In study patients with verified lateralised aldosterone or cortisol overproduction to the left adrenal, outcome will be compared with control groups performing conventional unilateral adrenalectomy.\n\nStudy group 1: PA patients with AVS-verified left sided lateralisation and a EUS-detectable tumour in the left adrenal for EUS-RFA treatment.\n\nStudy group 2: PA patient with suspected left-sided overweight of aldosterone production and a EUS-detectable tumour but without strict lateralisation of their aldosterone overproduction, for EUS-RFA treatment as an aldosterone \"debulking\" procedure.\n\nStudy group 3: patients with MACS with AVS-verified lateralisation of cortisol overproduction to the left adrenal and EUS-detectable tumour for EUS-RFA treatment Study group 4: patients with MACS with bilateral adrenal tumours and verified bilateral overproduction of cortisol for EUS-RFA treatment as a cortisol \"debulking\" procedure.",[27,155,156],"Aldosterone-Producing Adenoma","Hypercortisolism",[158,159,160,161],"radio frequency ablation","postoperative hypoaldosteronism","postoperative hypocortisolism","metabolic comorbidity","2026-05-07",{"date":164,"type":35},"2026-05-08",{"date":166,"type":35},"2022-06-03",{"date":168,"type":21},"2028-12-31",{"name":170,"class":42},"Haukeland University Hospital",{"id":172,"slug":173,"hasResults":12,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":4,"eligibilityCriteria":177,"healthyVolunteers":12,"sex":18,"minAge":51,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":22,"phases":179,"briefSummary":180,"conditions":181,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":191},"100629154","phase-2-a-phase-ii-clinical-study-on-the-efficacy-and-safety-of-hrs-1780-in-participants-with-primary-aldosteronism-100629154","NCT07470983","A Phase II Clinical Study on the Efficacy and Safety of HRS-1780 in Participants With Primary Aldosteronism","A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of HRS-1780 in Participants With Primary Aldosteronism","Inclusion Criteria:\n\n1. Male or female, aged ≥ 18 years on the date of signing the informed consent form.\n2. Diagnosed with primary aldosteronism.\n3. No use of antihypertensive drugs before screening, or stable use of antihypertensive drugs.\n4. Voluntarily sign the informed consent form before the trial, fully understand the trial content, procedures, and possible adverse reactions, and be capable and willing to comply with the protocol requirements to complete the study.\n5. From the signing of the informed consent form until 4 weeks after the last dose, the participant has no plan for procreation and is willing to adopt the highly effective contraceptive measures specified in the protocol.\n\nExclusion Criteria:\n\n1. Has known secondary causes of hypertension.\n2. Has previously undergone, or plans to undergo during the study period, adrenal-related surgeries, including adrenalectomy, adrenal ablation, etc.\n3. Estimated glomerular filtration rate (eGFR) \\\u003C 30 mL\u002Fmin\u002F1.73 m².\n4. Has had any malignancy of an organ system within 5 years before screening.\n5. Has received any other investigational drug within 90 days or 5 half-lives before screening (whichever is longer).\n6. Has a history of blood donation or blood loss ≥ 400 mL within 3 months before screening, or has received a blood transfusion within 2 months.\n7. Known or suspected alcohol or narcotic abuse.\n8. Women who are pregnant, breastfeeding, planning pregnancy, or of childbearing potential unable to adopt highly effective contraceptive measures; or men unable to adopt highly effective contraceptive measures.\n9. Abnormal daily routine.\n10. Use of strong inhibitors\u002Finducers of cytochrome P450 3A4 (CYP3A4) within 1 week before randomization.\n11. Severe infection, severe trauma, or major or medium-scale surgery within 1 month prior to screening;\n12. Stroke, transient ischemic attack, myocardial infarction, symptomatic heart failure (NYHA III-IV), or coronary revascularization within 3 months prior to screening; and\u002For planned coronary, carotid, or peripheral artery revascularization at the time of screening;\n13. Within 6 months prior to the screening period, participants have clinically significant diseases that, in the judgment of the investigator, may interfere with the trial results or pose additional risks to the administration of the study drug, including but not limited to respiratory, digestive, cardiovascular, endocrine, immune, urinary, adrenal (except for the primary disease), hematological, neurological, psychiatric, or other conditions;\n14. Presence or suspected presence of depression, bipolar disorder, suicidal tendencies, schizophrenia, or other severe mental disorders; or participants with mental incapacity or language barriers that prevent them from adequately understanding or participating in the trial process;\n15. Alanine aminotransferase (ALT) ≥ 3 × upper limit of normal (ULN);\n16. Aspartate aminotransferase (AST) ≥ 3 × ULN;\n17. In the judgment of the investigator, any condition that may affect participant safety or otherwise interfere with the evaluation of trial results (including medical, psychological, social, or geographical factors).",{"count":151,"type":21},[78],"This study is a multicenter, randomized, double-blind, placebo-parallel-controlled phase II clinical trial to evaluate the efficacy and safety of HRS-1780 compared with placebo in participants with primary aldosteronism. The study plans to enroll 60 participants.",[27],"2026-04-29",{"date":184,"type":35},"2026-04-30",{"date":186,"type":35},"2026-04-23",{"date":188,"type":21},"2026-11",{"name":190,"class":91},"Shandong Suncadia Medicine Co., Ltd.",2,{"id":193,"slug":194,"hasResults":12,"nctId":195,"briefTitle":196,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":12,"sex":18,"minAge":51,"maxAge":99,"enrollmentInfo":198,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":200,"conditions":201,"keywords":204,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":211,"locationsCount":43},"100589505","study-on-the-incidence-of-adrenal-insufficiency-after-surgery-in-primary-aldosteronism-patients-concurrent-with-or-without-autonomous-cortisol-secretion-100589505","NCT06955286","Study on the Incidence of Adrenal Insufficiency After Surgery in Primary Aldosteronism Patients Concurrent With or Without Autonomous Cortisol Secretion","* A confirmed diagnosis of primary aldosteronism or autonomous cortisol secretion;\n\n  ② Completion of unilateral adrenal surgery;\n\n  ③ Voluntary participation and obtaining informed consent. (2) Exclusion criteria\n* Patients with typical clinical manifestations of Cushing's syndrome;\n\n  * Patients suspected of having bilateral cortisol over-secretion, such as PBMAH or PPNAD; ③ Patients with severe surgical complications, unstable postoperative condition (not due to cortical insufficiency), and difficulty completing the ACTH stimulation test;\n\n    * History of ACTH allergy;\n\n      * Patients requiring long-term hormone therapy for other diseases (such as autoimmune diseases);\n\n        * Severe liver and kidney dysfunction (ALT ≥ 3 times the upper limit of normal; patients undergoing dialysis or with an estimated glomerular filtration rate \\\u003C 30 ml\u002Fmin\u002Fm2); ⑦ History of contralateral adrenal surgery; ⑧ Patients with poor compliance who are unable to complete the study.",{"count":199,"type":21},521,"To evaluate the incidence of adrenal insufficiency after surgery in Primary aldosteronism (PA) patients concurrent with or without autonomous cortisol secretion (ACS). To assess the recovery time of postoperative adrenal insufficiency in patients. And to explore the clinical characteristics and predictive indicators of patients requiring postoperative hormone replacement therapy.",[27,202,203],"Autonomous Cortisol Secretion","Adrenal Insufficiency",[27,202,203,205],"ACTH stimulation test",{"date":207,"type":35},"2026-05-01",{"date":209,"type":35},"2025-01-02",{"date":168,"type":21},{"name":212,"class":42},"Qifu Li",{"id":214,"slug":215,"hasResults":12,"nctId":216,"briefTitle":217,"officialTitle":217,"acronym":218,"eligibilityCriteria":219,"healthyVolunteers":12,"sex":18,"minAge":51,"maxAge":220,"enrollmentInfo":221,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":223,"conditions":224,"keywords":226,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":43},"100588416","steroids-based-screening-for-primary-aldosteronism-100588416","NCT06941116","Steroids-Based Screening for Primary Aldosteronism","SAFE","Inclusion Criteria:\n\n1. Aged 18-75 years, with no sex restriction.\n2. Diagnosed with hypertension, defined as a systolic blood pressure ≥140 mmHg and\u002For a diastolic blood pressure ≥90 mmHg measured on at least two different days.\n3. Currently receiving at least one antihypertensive medication that interferes with aldosterone or renin (ACEI\u002FARB, β-blockers, dihydropyridine CCBs, or diuretics including MRA) for ≥4 consecutive weeks.\n4. Fully informed about the study procedures and risks, and willing to participate by signing a written informed consent form.\n\nExclusion Criteria:\n\n1. Confirmed secondary hypertension of other etiologies (e.g., renovascular hypertension, renal artery stenosis, reninoma, pheochromocytoma, Cushing's syndrome, Liddle syndrome), excluding obstructive sleep apnea.\n2. Severe cardiac, hepatic, or renal impairment or serious infections, including but not limited to New York Heart Association (NYHA) Class III-IV heart failure, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 2.5 times the upper limit of normal, estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73 m², or severe infections (e.g., diabetic foot, sepsis, pneumonia, refractory infections).\n3. History of major cardiovascular or cerebrovascular events within the past 3 months.\n4. Pregnant or breastfeeding women.\n5. Currently using medications (other than the listed antihypertensives) that may affect aldosterone or renin secretion, including but not limited to sex hormones (e.g., oral contraceptives, estrogen replacement therapy), glucocorticoids (e.g., prednisone, dexamethasone), nonsteroidal anti-inflammatory drugs (NSAIDs, e.g., aspirin, ibuprofen), or antipsychotics (e.g., chlorpromazine, olanzapine).\n6. Individuals lacking or having restricted capacity for independent decision-making or action.\n7. History of psychiatric disorders.\n8. Poor compliance likely to compromise study completion.","75 Years",{"count":222,"type":21},406,"This prospective, single-center observational study aims to evaluate whether a steroid-based screening method can more accurately identify Primary Aldosteronism (PA) in hypertensive patients who remain on their usual antihypertensive medications, compared with the conventional aldosterone-to-renin ratio (ARR). PA is a common, potentially curable subtype of secondary hypertension that carries increased cardiovascular risk when undiagnosed or untreated. However, current screening protocols recommend \"medication washout\" or switching to minimally interfering drugs, which may pose safety concerns and add complexity.\n\nIn this study, approximately 406 participants (ages 18-75) with diagnosed hypertension and on at least one interfering antihypertensive drug (such as ACE inhibitors, ARBs, beta-blockers, diuretics, or calcium channel blockers) will be enrolled at the Department of Endocrinology, The First Affiliated Hospital of Chongqing Medical University. Each participant will undergo two rounds of blood sampling-first while continuing their usual antihypertensive regimen (the \"on-medication\" state) and second following a standardized washout\u002Fswitch period (the \"standard state\"), if medically feasible. At both stages, levels of plasma aldosterone, renin, and a broad panel of adrenal steroid hormones will be measured by liquid chromatography-tandem mass spectrometry.\n\nBy comparing diagnostic performance (e.g., sensitivity, specificity, and area under the receiver operating characteristic curve) of the steroid-based screening versus the ARR, the study seeks to determine whether steroid profiling improves accuracy under real-world treatment conditions. Findings may help refine PA screening strategies, reduce the need for extensive medication adjustments, and contribute to better clinical management of hypertension.",[27,225],"Hypertension",[227,228,229,27],"Steroid-Based Screening","Aldosterone-to-Renin Ratio (ARR)","Machine Learning",{"date":231,"type":35},"2026-04-28",{"date":233,"type":35},"2025-04-15",{"date":235,"type":21},"2026-12-30",{"name":212,"class":42},{"id":238,"slug":239,"hasResults":12,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":12,"sex":18,"minAge":51,"maxAge":4,"enrollmentInfo":244,"targetDuration":4,"studyType":22,"phases":245,"briefSummary":246,"conditions":247,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":252,"leadSponsor":254,"locationsCount":4},"100635267","phase-2-study-of-qls1410-in-the-treatment-of-primary-aldosteronism-100635267","NCT07550465","Study of QLS1410 in the Treatment of Primary Aldosteronism.","A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study to Evaluate the Efficacy and Safety of QLS1410 Tablets in the Treatment of Patients With Primary Aldosteronism.","Inclusion Criteria:\n\n1. Male or female participants must be ≥ 18 years of age\n2. Participants with a documented diagnosis of primary aldosteronism (PA) that fulfils the criteria Guidelines.\n3. Participants willing and able to cease dosing of mineralocorticoid receptor antagonist (MRA) or potassium sparing diuretics per study requirement for participants taking an MRA or potassium sparing diuretic at Screening.\n4. eGFR ≥ 45 mL\u002Fmin\u002F1.73m2 at Screening\n5. Have a stable regimen of antihypertensive medications for at least 4 weeks prior to randomization\n\nExclusion Criteria:\n\n1. Had undergone surgery for adrenal adenoma in the past or planned to receive surgical treatments such as adrenalectomy, renal sympathetic denervation, or adrenal ablation during the course of the study.\n2. Has the following known secondary causes of HTN: renal artery stenosis, uncontrolled or untreated hyperthyroidism, pheochromocytoma, Cushing's syndrome, aortic coarctation.\n3. Treatment with any MRA or potassium-sparing diuretic within 2 weeks prior to Randomization.",{"count":151,"type":21},[78],"This is a Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety, tolerability, and efficacy of QLS1410 versus placebo, on the reduction of Seated Blood Pressure (SBP) in participants ≥ 18 years of age with Primary Aldosteronism (PA) with or without prior treatment with Mineralocorticoid Receptor Antagonists (MRAs) or potassium-sparing diuretics.\n\nQLS1410 (or placebo) will be administered once daily, up-titrated after 2 weeks or 4 weeks based on clinical response and tolerability.",[27],"2026-04-19",{"date":250,"type":35},"2026-04-24",{"date":37,"type":21},{"date":253,"type":21},"2027-04",{"name":255,"class":91},"Qilu Pharmaceutical Co., Ltd.",{"id":257,"slug":258,"hasResults":12,"nctId":259,"briefTitle":260,"officialTitle":260,"acronym":261,"eligibilityCriteria":262,"healthyVolunteers":12,"sex":18,"minAge":51,"maxAge":4,"enrollmentInfo":263,"targetDuration":4,"studyType":22,"phases":265,"briefSummary":266,"conditions":267,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":43},"100524415","renin-guided-therapy-with-mineralocorticoid-receptor-antagonists-in-primary-aldosteronism---feasibility-study-100524415","NCT06108427","REnin-guided TherApy With MinEralocorticoid Receptor Antagonists in Primary Aldosteronism - Feasibility Study","RETAME-PA","Inclusion Criteria:\n\n* Over 18 years of age\n* Diagnosis of PA, in accordance with clinical guidelines and local practice\n* Suppressed plasma renin prior to treatment initiation (plasma renin concentration \\>15 mIU\u002FL or \\>10 ng\u002FL, or plasma renin activity \\>1 ng\u002FmL\u002Fh)\n* Planned long-term treatment with mineralocorticoid receptor antagonist\n\nExclusion Criteria:\n\n* Prior use of mineralocorticoid receptor antagonist or any potassium-sparing diuretics in the past 3 months\n* Known intolerance or contraindication to mineralocorticoid receptor antagonist treatment\n* eGFR \\\u003C 30 ml\u002Fmin\u002F1.73m2 (past 3 months)\n* Baseline serum potassium above \\> 4.8 mmol\u002FL (past 3 months)\n* Deemed medically unsafe to stop medications for the initiation of MRA as monotherapy\n* Pregnancy or breastfeeding\n* Participation in another study that is likely to affect renin or BP levels\n* Inability to provide consent due to cognitive impairment and\u002For language barrier.",{"count":264,"type":21},58,[24],"High blood pressure, or hypertension, can be caused by a condition called Primary Aldosteronism (PA), where the body produces too much of a hormone called aldosterone. People with PA have a higher risk of heart problems compared to those with regular high blood pressure. To treat PA, some patients need to take medicine called mineralocorticoid receptor antagonists (MRA) for the rest of their lives. While treatment with MRA is effective, it can have side effects like high levels of potassium in the blood, breast enlargement in men, menstrual problems in women, and reduced sex drive. Finding the right dose of MRA for each patient can be tricky.\n\nRecent observations suggest that when a hormone called renin goes up during MRA treatment, it might be a good sign. This is because renin is higher when the action of aldosterone is well blocked. But it's not certain if this happens because of the patient's unique characteristics or if it can truly be a way to know if the treatment is working.\n\nThis study aims to find out if guiding MRA treatment with renin levels leads to more patients having unsuppressed renin levels compared to the standard of care.\n\nThis is a multicentric pragmatic clinical trial. Patients with a new diagnosis of PA and low renin levels will be asked if there are willing to participate. Those with recent use of MRA, known MRA intolerance, severe kidney problems, or have high potassium levels will not be able to participate.\n\nParticipants will be randomized into two groups: one group will have their MRA treatment adjusted based on renin levels (the \"renin-guided\" group), and the other group won't have renin levels checked during treatment (the \"renin-blinded\" group). Both groups will aim to have their blood pressure under control and potassium levels in the normal range.\n\nThe main outcome is the proportion in each group with unsuppressed renin levels after 12 months. Other outcomes will be tested, such as changes in renin levels, how well the treatment works, and any safety concerns (like potassium levels, kidney function, side effects, and blood pressure changes). Different groups of patients will also be looked at separately, like men and women, different ages, races, and initial renin levels, to see if the approach works better for some people.\n\nThis study will help find a safe and effective way to treat PA with MRA. Choosing the right dose of MRA is important to adequately block aldosterone but also to avoid side effects.",[27],"2026-03-16",{"date":270,"type":35},"2026-03-17",{"date":272,"type":35},"2024-04-25",{"date":274,"type":21},"2027-09",{"name":276,"class":42},"Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal",{"id":278,"slug":279,"hasResults":12,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":283,"eligibilityCriteria":284,"healthyVolunteers":12,"sex":18,"minAge":51,"maxAge":4,"enrollmentInfo":285,"targetDuration":4,"studyType":22,"phases":287,"briefSummary":288,"conditions":289,"keywords":290,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":303},"100470380","randomised-trial-comparing-thermal-ablation-with-adrenalectomy-in-the-treatment-of-unilateral-asymmetric-pa-100470380","NCT05405101","Randomised Trial Comparing Thermal Ablation With Adrenalectomy in the Treatment of Unilateral Asymmetric PA","A Prospective Randomised Trial Comparing Thermal Ablation With Laparoscopic Adrenalectomy as an alternatiVE Treatment for Unilateral Asymmetric Primary Aldosteronism","WAVE","Inclusion criteria (all of):\n\n* Age \\> 18 years\n* Primary aldosteronism diagnosed according to international guidelines\n* Unilateral disease by AVS or PET-CT criteria\n* Ipsilateral radiological abnormality with benign imaging characteristics and technically amenable to both thermal ablation and surgery\n* Able and willing to give informed consent\n* Randomisation approved by MDT\n\nExclusion criteria (any of):\n\n* Absolute contraindication to α- or β-adrenoceptor antagonist therapy or CT contrast\n* Contraindication or unwillingness for either surgery or thermal ablation\n* Inability to withdraw β-adrenoceptor antagonist therapy for 2 weeks\n* Unwilling to undergo either LA or thermal ablation\n* Unwilling to comply with study visit schedule\n* Pregnancy or unwillingness to undertake secure contraception for the study duration (female participants only)\n* Life-limiting comorbidity (at the discretion of the PI)\n* Clinical and\u002For biochemical evidence of autonomous cortisol secretion sufficient, in the opinion of the patient's physician, to mandate a unilateral adrenalectomy independent of autonomous aldosterone secretion",{"count":286,"type":21},122,[24],"The primary objective of WAVE is to test the hypothesis that thermal ablation (microwave or RFA) is non-inferior to surgery in the biochemical (and if so, in the clinical) cure of unilateral PA, according to the international consensus PASO criteria.\n\nSecondary objectives are to determine whether either intervention is superior to the other in relation to the following outcomes. Where no superiority of either intervention is established, non-inferiority of thermal ablation against adrenalectomy will be sought.\n\n* Frequency and severity of adverse events\n* Length of inpatient stay\n* Patient satisfaction\n* Quality of life\n* Return to activities of daily living\n\nAn additional secondary objective in the thermal ablation group alone will be anatomical efficacy of ablation.",[27],[291,292,293,294],"Thermal","Ablation","Laparoscopic","Adrenalectomy","2026-02-19",{"date":297,"type":35},"2026-02-23",{"date":299,"type":35},"2022-09-01",{"date":301,"type":21},"2026-09-01",{"name":67,"class":42},6,{"id":305,"slug":306,"hasResults":12,"nctId":307,"briefTitle":308,"officialTitle":309,"acronym":4,"eligibilityCriteria":310,"healthyVolunteers":12,"sex":18,"minAge":51,"maxAge":99,"enrollmentInfo":311,"targetDuration":4,"studyType":22,"phases":313,"briefSummary":314,"conditions":315,"keywords":316,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":324,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":43},"100580141","68ga-pentixafor-petct-versus-adrenal-vein-sampling-in-diagnosing-unilateral-subtype-of-primary-aldosteronism-concurrent-with-autonomous-cortisol-secretion-predict-100580141","NCT06833437","68Ga-Pentixafor PET\u002FCT Versus Adrenal Vein Sampling in Diagnosing Unilateral Subtype of Primary Aldosteronism Concurrent With Autonomous Cortisol Secretion (PREDICT)","68Ga-Pentixafor PET\u002FCT Versus Adrenal Vein Sampling in Diagnosing Unilateral Subtype of Primary Aldosteronism Concurrent With Autonomous Cortisol Secretion (PREDICT): a Randomized Cross-over Trial","Inclusion Criteria:\n\n* Getting the written informed consent;\n* PA conccurent with autonomous cortisol secretion;\n* Patients with hypertension aged 18-70 years;\n* CT or MRI scan of the adrenal glands with adenoma. Exclusion criteria\n\nExclusion Criteria:\n\n* Unable to complete 68Ga-Pentixafor PET\u002FCT or AVS;\n* Refusal of surgery or contraindications for surgery;\n* PA patients who meet the by-passing AVS criteria \\[i.e., younger than 35 years old, spontaneous hypokalemia, adrenal CT indicated unilateral low-density adenoma (≥1cm), plasma aldosterone \\>300pg\u002Fml\\]\n* Suspicion of familial hyperaldosteronism or Liddle syndrome. \\[i.e., age \\\u003C20 years, hypertension and hypokalemia, or with family history\\];\n* Suspicion of pheochromocytoma or adrenal carcinoma;\n* Patients with actively malignant tumor;\n* Patients who have adrenalectomy history;\n* Long-term use of glucocorticoids;\n* Pregnant or lactating women; with alcohol or drug abuse and mental disorders;\n* Congestive heart failure with New York Heart Association (NYHA) Functional Classification III or IV; History of serious cardiovascular or cerebrovascular disease (angina, myocardial infarction or stroke) in the past 3 months; Severe anemia (Hb\\\u003C60g\u002FL); Serious liver dysfunction or chronic kidney disease aspartate aminotransferase (AST) or alanine transaminase (ALT) \\>3 times the upper limit of normal, or estimated glomerular filtration rate (eGFR) \\\u003C 30 ml\u002Fmin\u002F1.73 m2); Systemic Inflammatory Response Syndrome (SIRS); Uncontrolled diabetes (FBG≥13.3 mmol\u002FL); Obesity (BMI≥35 kg\u002Fm²) or Underweight (BMI≤18 kg\u002Fm²); Untreated aneurysm; Other comorbidity potentially interfering with treatment;\n* Suspected PBMAH or PPNAD;\n* Poor compliance or any other reason deemed unsuitable for inclusion by the investigators;\n* Patients with adrenal insufficiency requiring hormone replacement therapy.",{"count":312,"type":21},178,[24],"To validate the accuracy of 68Ga-Pentixafor PET\u002FCT and adrenal venous sampling (AVS) in subtype diagnosis of PA\u002FACS patients with adrenal nodules, based on biochemical and clinical remission outcomes, and to determine whether the diagnostic accuracy of 68Ga-Pentixafor PET\u002FCT is non-inferior to AVS.",[27,202],[317,318,319,320,321,322],"Primary aldosteronism","Autonomous cortisol secretion","Adrenal venous sampling","68Ga-Pentixafor PET\u002FCT","outcome","multicenter randomized crossover trial","2026-02-03",{"date":325,"type":35},"2026-02-05",{"date":327,"type":35},"2024-08-01",{"date":329,"type":21},"2029-12-31",{"name":212,"class":42},{"id":332,"slug":333,"hasResults":12,"nctId":334,"briefTitle":335,"officialTitle":335,"acronym":336,"eligibilityCriteria":337,"healthyVolunteers":12,"sex":18,"minAge":51,"maxAge":149,"enrollmentInfo":338,"targetDuration":340,"studyType":54,"phases":4,"briefSummary":341,"conditions":342,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":191},"100622019","prognosis-of-primary-aldosteronism-a-prospective-cohort-study-100622019","NCT07378176","Prognosis of Primary Aldosteronism: A Prospective Cohort Study","PA-PROG","Inclusion Criteria:\n\n1. Aged between 18 and 80 years old.\n2. Biochemically confirmed diagnosis of Primary Aldosteronism (PA) according to contemporary guidelines (e.g., confirmed positive case detection test and confirmatory test).\n3. Voluntary to sign the informed consent.\n\nExclusion Criteria:\n\n1. patients with severe cardiac, hepatic or renal dysfunction;\n2. Diagnosis of secondary hypertension other than PA.",{"count":339,"type":21},5000,"60 Months","Primary aldosteronism (PA) is the most common cause of secondary hypertension, and patients with PA have a significantly higher risk of developing cardiovascular and renal complications compared with those with essential hypertension. However, PA remains substantially underdiagnosed and undertreated in clinical practice, and relevant research data on the short-term and long-term prognosis of PA patients in the Chinese population are particularly scarce. This is a multicenter, prospective cohort study designed to systematically collect real-world clinical data of PA patients, including baseline clinical characteristics, etiological subtypes, diagnostic and therapeutic strategies, and long-term follow-up outcomes. Through 5 years of standardized follow-up, this study will analyze the differences in treatment efficacy among PA patients with different pathological subtypes (e.g., adrenal adenoma, adrenal hyperplasia), evaluate the short-term therapeutic efficacy and long-term prognosis of PA patients undergoing different treatment modalities including pharmacotherapy, surgery and interventional therapy, and explore the risk factors for adverse clinical outcomes. Ultimately, it will provide high-quality real-world evidence-based data to optimize the clinical diagnosis and management of PA and improve the long-term prognosis of affected patients.",[27],"2026-02-02",{"date":323,"type":35},{"date":346,"type":35},"2026-01-30",{"date":348,"type":21},"2031-12",{"name":350,"class":42},"Xinjiang Medical University",{"id":352,"slug":353,"hasResults":12,"nctId":354,"briefTitle":355,"officialTitle":355,"acronym":356,"eligibilityCriteria":357,"healthyVolunteers":12,"sex":18,"minAge":358,"maxAge":4,"enrollmentInfo":359,"targetDuration":340,"studyType":54,"phases":4,"briefSummary":361,"conditions":362,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":372,"locationsCount":191},"100616366","the-association-between-primary-aldosteronism-and-cognitive-dysfunction-100616366","NCT07304674","The Association Between Primary Aldosteronism and Cognitive Dysfunction","PACD","Inclusion Criteria:\n\n* 1\\. Aged ≥ 40 years.\n* 2\\. Biochemically confirmed diagnosis of Primary Aldosteronism (PA) according to contemporary guidelines (e.g., confirmed positive case detection test and confirmatory test).\n* 3\\. Ability to understand and cooperate with comprehensive neuropsychological assessment.\n* 4\\. Voluntary participation and provision of written informed consent.\n\nExclusion Criteria:\n\n* 1\\. Significant visual, hearing, or motor impairment that prevents completion of cognitive testing.\n* 2\\. History of major neurological disorders (e.g., stroke, Parkinson's disease, intracranial tumor, severe traumatic brain injury).\n* 3\\. History of major psychiatric illness, intellectual disability, or current use of antipsychotic medications.\n* 4\\. Diagnosis of secondary hypertension other than PA.\n* 5\\. Unwillingness to participate by the patient or their legal representative.","40 Years",{"count":360,"type":21},1000,"The goal of this observational study is to learn about the prevalence, progression, and influencing factors of cognitive impairment in patients with primary aldosteronism (PA). The main questions it aims to answer are:\n\n1. What is the prevalence of baseline cognitive impairment in PA patients and what factors are associated with it?\n2. What is the incidence of cognitive progression in PA patients within 1 and 5 years of follow-up and what factors influence this progression? Participants who are already diagnosed with PA as part of their regular medical care will be invited to join this long-term study. They will complete regular cognitive tests, medical check-ups, and questionnaires for up to 5 years. Some participants will also have optional blood tests and brain scans to help researchers understand the causes behind any cognitive changes.",[27,363,364,365],"Cognitive Dysfunction","Mild Cognitive Impairment (MCI)","Dementia","2026-01-01",{"date":368,"type":35},"2026-01-05",{"date":370,"type":35},"2025-12-31",{"date":348,"type":21},{"name":350,"class":42},{"id":374,"slug":375,"hasResults":12,"nctId":376,"briefTitle":377,"officialTitle":378,"acronym":4,"eligibilityCriteria":379,"healthyVolunteers":12,"sex":18,"minAge":51,"maxAge":99,"enrollmentInfo":380,"targetDuration":4,"studyType":22,"phases":382,"briefSummary":383,"conditions":384,"keywords":385,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":390,"lastUpdatePostDateStruct":391,"startDateStruct":393,"completionDateStruct":395,"leadSponsor":396,"locationsCount":43},"100615926","sequential-combined-versus-single-strategy-adrenal-venous-sampling-for-primary-aldosteronismscope-100615926","NCT07298954","Sequential Combined Versus Single-Strategy Adrenal Venous Sampling for Primary Aldosteronism(SCOPE)","Sequential Combined Versus Single-Strategy Adrenal Venous Sampling for Primary Aldosteronism: A Multicenter, Randomized Trial","Inclusion Criteria:\n\n* Fully understand the study process, voluntarily agree to participate, and sign informed consent.\n* Diagnosed with primary aldosteronism. # Age 18-70 years with hypertension, any sex.\n\nExclusion Criteria:\n\n* Patients for whom AVS can be bypassed: Typical BPA (normal serum potassium and plasma aldosterone concentration (PAC) \\\u003C 110 pg\u002FmL, eligible for direct medical therapy); Typical UPA (PAC ≥ 200 pg\u002FmL, plasma renin concentration (PRC) ≤ 5 μIU\u002FmL, spontaneous hypokalemia, unilateral adrenal adenoma ≥ 1 cm with normal contralateral adrenal on CT or 68Ga-Pentixafor PET-CT indicating unilateral functional tumor, eligible for direct surgery);\n* Refusal of AVS or surgery, or contraindication to surgery.\n* Allergy to ACTH or contrast agents.\n* Combined with autonomous cortisol secretion (1 mg overnight dexamethasone suppression test cortisol ≥ 50 nmol\u002FL).\n* Early-onset hypertension (\\\u003C20 years) with hypokalemia and family history, suggestive of familial hyperaldosteronism or Liddle syndrome.\n* Imaging cannot exclude pheochromocytoma or adrenocortical carcinoma (nodule ≥ 4 cm, CT ≥ 20 HU, or MRI suggestive).\n* Active malignancy.\n* Previous adrenal surgery.\n* Chronic glucocorticoid use that cannot be discontinued.\n* Adrenal insufficiency requiring hormone replacement.\n* Pregnancy or breastfeeding; history of alcohol or substance abuse, or inability to cooperate due to psychiatric disorders.\n* NYHA class III-IV heart failure or hospitalization for worsening heart failure in the past 3 months, stroke or acute coronary syndrome in past 3 months, severe anemia (Hb \\\u003C 60 g\u002FL), severe liver or renal disease (ALT ≥ 3×upper limit; eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m2 or dialysis), systemic inflammatory response syndrome (SIRS), poorly controlled diabetes (FBG ≥ 13.3 mmol\u002FL), severe obesity (BMI ≥ 35 kg\u002Fm2), untreated aneurysm, or other conditions severely interfering with study participation.",{"count":381,"type":21},456,[24],"This study is a prospective, multicenter, randomized clinical trial aimed to compare the impact of three AVS diagnostic strategies on the clinical outcomes of patients with primary aldosteronism. The strategies include sequential combined AVS (non-ACTH-stimulated followed by ACTH-stimulated AVS), non- ACTH-stimulated AVS alone, and ACTH-stimulated AVS alone. The findings of this study will provide critical evidence for the clinical practice standards of AVS.",[27],[27,319,386,387,388,389],"sequential combined AVS","non-ACTH-stimulated","ACTH-stimulated AVS","complete biochemical remission rate","2025-12-22",{"date":392,"type":35},"2025-12-24",{"date":394,"type":21},"2025-12-25",{"date":168,"type":21},{"name":397,"class":42},"Shumin Yang",{"id":399,"slug":400,"hasResults":12,"nctId":401,"briefTitle":402,"officialTitle":403,"acronym":4,"eligibilityCriteria":404,"healthyVolunteers":12,"sex":18,"minAge":51,"maxAge":220,"enrollmentInfo":405,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":407,"conditions":408,"keywords":409,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":413,"lastUpdatePostDateStruct":414,"startDateStruct":416,"completionDateStruct":418,"leadSponsor":420,"locationsCount":43},"100482386","the-effect-of-saae-on-vascular-endothelial-function-in-pa-patients-100482386","NCT05561361","The Effect of SAAE on Vascular Endothelial Function in PA Patients","The Effect of Selective Adrenal Artery Embolism on Vascular Endothelial Function in Patients With Primary Aldosteronism Based on Brachial Artery Flow-mediated Relaxation","Inclusion Criteria:\n\n* (1)Aged 18-75 years, males and females;\n* (2)Blood pressure ≥ 140\u002F90 mmHg on at least three non-same-day office visits without antihypertensive medication or 24-hour ambulatory blood pressure averaging \\>130\u002F80 mmHg throughout the day or averaging \\>135\u002F85 mmHg during the day;\n* (3)Primary aldosteronism was diagnosed in accordance with the 2016 international society of Endocrinology clinical guidelines after strict drug elution;\n* (4)Contraindications to spironolactone-free administration;\n* (5)No surgical intention or surgical contraindications, and willing to accept drug treatment or percutaneous superselective adrenal artery embolization;\n* (6)The anatomy of adrenal arteriography is suitable for selective adrenal artery embolization.\n\nExclusion Criteria:\n\n* (1)Secondary hypertension of other causes;\n* (2)Pregnant women or those who have a fertility plan in the next year;\n* (3)Glomerular filtration rate EGFR \\\u003C 45 ml\u002Fmin\u002F1.73m\\^2;\n* (4)History of severe contrast allergy;\n* (5)Hyperkalemia;\n* (6)Patients with other serious organic diseases or life expectancy \\\u003C 12 months can not tolerate the treatment of super selective adrenal artery embolizatio;\n* (7)The diameter of adrenal space occupying lesions was more than 2 cm;\n* (8)A history of myocardial infarction, syncope, cerebral hemorrhage or cerebral infarction within 3 months before the informed consent;\n* (9)The results of this study will be affected during the period when patients are enrolled or will participate in other clinical studies.",{"count":406,"type":21},200,"The study aims to assess the effect of superselective adrenal arterial embolization on vascular endothelial function in patients with primary aldosteronism based on brachial artery flow-mediated relaxation",[27],[410,411,412],"primary aldosteronism","selective adrenal artery embolization","vascular endothelial function","2025-12-07",{"date":415,"type":35},"2025-12-15",{"date":417,"type":35},"2022-10-01",{"date":419,"type":21},"2026-12-31",{"name":421,"class":42},"Second Affiliated Hospital of Nanchang University",{"id":423,"slug":424,"hasResults":12,"nctId":425,"briefTitle":426,"officialTitle":426,"acronym":4,"eligibilityCriteria":427,"healthyVolunteers":98,"sex":18,"minAge":51,"maxAge":149,"enrollmentInfo":428,"targetDuration":430,"studyType":54,"phases":4,"briefSummary":431,"conditions":432,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":433,"lastUpdatePostDateStruct":434,"startDateStruct":436,"completionDateStruct":438,"leadSponsor":440,"locationsCount":43},"100601504","multi-omics-studies-of-primary-aldosteronism-100601504","NCT07111351","Multi-omics Studies of Primary Aldosteronism","Inclusion Criteria:\n\n1. Diagnosed with primary aldosteronism , primary hypertension , or age- and sex-matched healthy controls;\n2. Aged 18-80 years with complete medical records;\n3. Willing to participate voluntarily and provide informed consent.\n\nExclusion Criteria:\n\n1. History of chemotherapy or radiotherapy in the adrenal region ;\n2. Positive serological or nucleic acid test results for HIV, hepatitis B, or hepatitis C , or a prior confirmed diagnosis;\n3. Individuals with malignancies or autoimmune disorders ;\n4. Study withdrawal during the trial period",{"count":429,"type":21},400,"1 Month","Primary aldosteronism is a prevalent yet underdiagnosed cause of secondary hypertension, contributing to significant cardiovascular morbidity and renal dysfunction. Despite affecting up to 20% of hypertensive patients, PA is frequently missed because it lacks distinctive clinical features and often presents with nonspecific symptoms like resistant hypertension or subtle electrolyte imbalances. The diagnostic pathway involves a stepwise approach: initial screening via the aldosterone-to-renin ratio, confirmatory testing (e.g., saline suppression or captopril challenge), and subtype differentiation using adrenal venous sampling to distinguish unilateral adenoma from bilateral hyperplasia. This complexity, combined with clinician unfamiliarity and variable access to specialized centers, perpetuates underdiagnosis. Early identification and tailored treatment are paramount in improving outcomes for patients with primary aldosteronism.\n\nIn this study, we will conduct a comprehensive multi-omics analysis on three sample types: 1) blood and urine samples from patients with primary aldosteronism, primary hypertension, and healthy controls; and 2) adrenal tissue samples from patients undergoing adrenalectomy for aldosterone-producing adenomas. We aim to systematically identify differentially expressed biomarkers that could serve as potential early diagnostic markers for primary aldosteronism. The findings may provide new insights into disease pathogenesis and contribute to improving early detection and personalized treatment strategies for this condition.",[27],"2025-12-02",{"date":435,"type":35},"2025-12-09",{"date":437,"type":35},"2025-08-15",{"date":439,"type":21},"2029-05-31",{"name":441,"class":42},"Peking University First Hospital",{"id":443,"slug":444,"hasResults":12,"nctId":445,"briefTitle":446,"officialTitle":447,"acronym":448,"eligibilityCriteria":449,"healthyVolunteers":12,"sex":18,"minAge":358,"maxAge":220,"enrollmentInfo":450,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":452,"conditions":453,"keywords":454,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":462,"startDateStruct":464,"completionDateStruct":466,"leadSponsor":468,"locationsCount":43},"100573020","overnight-dexamethasone-in-primary-aldosteronism-screening-100573020","NCT06740838","Overnight Dexamethasone in Primary Aldosteronism Screening","Overnight Dexamethasone in Primary Aldosteronism Screening in Patients on Interfering Therapy (the ODEPRASC Study)","ODEPRASC","Inclusion Criteria:\n\n* suspected or diagnosed HT,\n* age between 40 and 75,\n* available aldosterone and renin result at the time of one-day clinic stay,\n* scheduled 1-mg-DXM test (indicated for possible mild autonomous cortisol secretion, MACS),\n* presence of an adrenal lesion with radiologic features of adrenocortical adenoma\u002Fhyperplasia.\n\nExclusion Criteria:\n\n* baseline (pre-DXM) hyperreninemia (renin exceeding the upper limit of normal at the study site, i.e. 46.1 mIU\u002Fl, assay manufacturer: Diasorin),\n* baseline (pre-DXM) Ald\\\u003C3 ng\u002Fdl,\n* overt clinical and\u002For biochemical features of adrenal hormone deficiency or excess other than MACS (8 a.m. cortisolemia in the 50-140 nmol\u002Fl range in the 1-mg DXM test),\n* therapy with glucocorticoids, non-steroidal anti-inflammatory drugs, hormonal replacement therapy, hormonal contraceptive therapy, and\u002For licorice intake,\n* established or suspected secondary HT other than due to PA,\n* comorbidities including: poorly controlled and\u002For other than type 2 diabetes mellitus (T2DM), present and past alcohol abuse, obesity grade 3 (i.e. body mass index of at least 40 kg\u002Fm2), severe CV disease disqualifying a patient from chronic medication modification, active malignancy, decompensated autoimmune disease as well as an autoimmune disease associated with cardiovascular and\u002For renal complications, estimated glomerular filtration rate (eGFR) below 45 ml\u002Fmin\u002F1.73m2, poor physical condition, lack and withdrawal of consent for participation.",{"count":451,"type":21},240,"The goal of this observational study is to learn whether screening for primary aldosteronism can be improved among patients on chronic blood pressure-lowering medications by ordering intake of 1 mg of dexamethasone prior to hormonal examinations.\n\nPrimary aldosteronism is a condition, in which an adrenal gland steroid aldosterone is released in excessive amounts; it commonly causes hypertension but requires specific therapy different from usually prescribed in other forms of hypertension.\n\nDexamethasone is a synthetic steroid used for both therapeutic and diagnostic purposes. A single 1 mg dexamethasone dose taken at 11 p.m. in order to measure hormone concentrations the following morning (so called overnight 1-mg dexamethasone test) is a commonly applied test in the work-up of adrenal disorders.\n\nThe main question the project aims to answer is:\n\nCan screening for primary aldosteronism be improved among patients receiving blood pressure-lowering medications with overnight 1-mg dexamethasone intake?\n\nParticipants will undergo changes in their chronic medication to be able to definitely rule out or confirm primary aldosteronism in blood hormonal examinations. These modifications and modifications are not part of the research project.\n\nFor this project participants will be asked to\n\n* undergo the 1-mg dexamethasone test one to three times in order to compare hormonal concentrations before and after it,\n* collect urine for 24 hours to determine aldosterone in the urine sample after medications interfering in aldosterone release are temporarily withdrawn.",[27,225],[410,455,456,457,458,459,460],"screening","renin","aldosterone","hypertension","corticotropin","dexamethasone","2025-09-27",{"date":463,"type":35},"2025-10-02",{"date":465,"type":35},"2024-10-22",{"date":467,"type":21},"2026-10-31",{"name":469,"class":42},"Medical University of Gdansk",{"id":471,"slug":472,"hasResults":12,"nctId":473,"briefTitle":474,"officialTitle":474,"acronym":4,"eligibilityCriteria":475,"healthyVolunteers":12,"sex":18,"minAge":476,"maxAge":477,"enrollmentInfo":478,"targetDuration":480,"studyType":54,"phases":4,"briefSummary":481,"conditions":482,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":483,"startDateStruct":485,"completionDateStruct":487,"leadSponsor":488,"locationsCount":43},"100603503","efficacy-of-spironolactone-combined-with-antihypertensive-drugs-in-patients-with-primary-aldosteronism-100603503","NCT07137364","Efficacy of Spironolactone Combined With Antihypertensive Drugs in Patients With Primary Aldosteronism","Inclusion Criteria:\n\n1. Male or female, aged 30\\~65 years.\n2. PA patients with positive screening tests and saline suppression tests, and with AVS to determine lateralization. These patients have hypertension defined as office blood pressure ≥ 140\u002F90 mmHg, or 24-hour ambulatory blood pressure showing average ≥ 130\u002F80 mmHg, daytime blood pressure ≥ 135\u002F85 mmHg, or nighttime blood pressure ≥ 120\u002F70 mmHg.\n3. Patients with unilateral aldosterone-producing adenoma who decline surgery, or patients with non-adenoma, unilateral PA confirmed by AVS and meeting the above PA-related hypertension criteria.\n4. Provision of written informed consent to participate in the study.\n\nExclusion Criteria:\n\n1. Hyperkalemia.\n2. Renal impairment or have history of renal disease: serum creatinine \\> 1.5 × upper limit of normal (ULN), dialysis, or nephrotic syndrome.\n3. Other confirmed secondary hypertension: pheochromocytoma, Cushing's syndrome, thyroid disorders, parathyroid disorders, acromegaly, renovascular disease, aortic disorders, chronic alcoholism, or drug dependence, etc.\n4. Adrenal insufficiency.\n5. Heart failure with NYHA class II-IV or stroke.\n6. Acute infection, malignancy, severe arrhythmia, psychiatric disorders, or drug\u002Falcohol abuse.\n7. Significant hepatic dysfunction or have history of liver disease: AST or ALT \\> 2 × ULN, cirrhosis, hepatic encephalopathy, esophageal varices or portosystemic shunt.\n8. Pregnancy or lactation.\n9. Participation in another clinical trial within the past 3 months.\n10. Inability to complete follow-up.\n11. Refusal to provide informed consent.","30 Years","65 Years",{"count":479,"type":21},350,"12 Months","The goal of this observational study is to learn about the optimal dose of spironolactone treatment and the long-term outcomes on cardiovascular and cerebrovascular events in patients with lateralized PA who are unwilling to undergo surgery. The main question it aims to answer is:\n\n1. What is the long-term effect of spironolactone treatment for lateralized PA?\n2. What is the optimal dose of spironolactone treatment for the relief of renin inhibition in patients with lateralized PA? Participants will receive spironolactone treatment as part of their regular medical care for more than 12 months, and their clinical indicators, including blood pressure, biochemical remission, cardiovascular and renal damage, and the incidence of cardiovascular and cerebrovascular events, will be analyzed.",[27,225],{"date":484,"type":35},"2025-08-22",{"date":486,"type":35},"2022-05-01",{"date":184,"type":21},{"name":489,"class":42},"Third Military Medical University",{"id":491,"slug":492,"hasResults":12,"nctId":493,"briefTitle":494,"officialTitle":495,"acronym":4,"eligibilityCriteria":496,"healthyVolunteers":12,"sex":18,"minAge":497,"maxAge":4,"enrollmentInfo":498,"targetDuration":4,"studyType":22,"phases":500,"briefSummary":501,"conditions":502,"keywords":505,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":512,"lastUpdatePostDateStruct":513,"startDateStruct":515,"completionDateStruct":517,"leadSponsor":519,"locationsCount":191},"100595038","petal-trial-impact-of-gallium-68-pentixafor-pet-ct-on-surgical-outcomes-in-primary-aldosteronism-100595038","NCT07027254","PETAL Trial: Impact of Gallium-68 Pentixafor PET-CT on Surgical Outcomes in Primary Aldosteronism","A Randomized Controlled Trial to Evaluate the Effect of Gallium-68 Pentixafor PET-CT on Surgical Outcomes in Patients With Primary Aldosteronism (The PETAL Trial)","Inclusion Criteria:\n\n* Age ≥19 years\n* Diagnosed with PA per 2016 Endocrine Society guidelines\n* Underwent adrenal CT\n* Signed informed consent\n\nExclusion Criteria:\n\n* Women who are pregnant, breastfeeding, or may become pregnant\n* Individuals who refuse to undergo surgery\n* Individuals for whom 68Ga-Pentixafor PET\u002FCT, 11C-Metomidate PET\u002FCT, or adrenal venous sampling (AVS) is not feasible or is refused due to underlying conditions\n* Individuals who refuse or experience adverse effects from dexamethasone premedication required for 11C-Metomidate PET\u002FCT\n* Individuals with a history of abdominal open surgery or retroperitoneal surgery on the same side as the planned adrenalectomy\n* Any individual deemed unsuitable for the study at the discretion of the investigator","19 Years",{"count":499,"type":21},90,[24],"This study is a randomized controlled trial to assess the clinical utility of gallium-68 pentixafor PET\u002FCT in the management of primary aldosteronism (PA). We aim to evaluate whether the addition of 68Ga-pentixafor PET\u002FCT to standard adrenal venous sampling (AVS) improves surgical outcomes in patients with unilateral PA.",[27,503,155,504,294],"Secondary Hypertension","Idiopathic Hyperaldosteronism",[317,506,507,508,509,510,511,294],"Gallium-68 pentixafor","11C-metomidate","PET\u002FCT","adrenal venous sampling","PASO","PAMO","2025-06-16",{"date":514,"type":35},"2025-06-18",{"date":516,"type":21},"2025-06-25",{"date":518,"type":21},"2027-12-01",{"name":141,"class":42},{"id":521,"slug":522,"hasResults":12,"nctId":523,"briefTitle":524,"officialTitle":525,"acronym":526,"eligibilityCriteria":527,"healthyVolunteers":12,"sex":18,"minAge":528,"maxAge":99,"enrollmentInfo":529,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":531,"conditions":532,"keywords":534,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":538,"lastUpdatePostDateStruct":539,"startDateStruct":541,"completionDateStruct":543,"leadSponsor":545,"locationsCount":547},"100559857","tissue-sodium-quantification-in-patients-with-primary-aldosteronism-see-sodium-to-treat-100559857","NCT06569589","Tissue Sodium Quantification in Patients With Primary Aldosteronism: See Sodium to Treat","Tissue Sodium Quantification in Patients With Primary Aldosteronism","SSTT","Inclusion Criteria:\n\n1. Age 21-70 years, with arterial hypertension or suspected to have primary aldosteronism based on Endocrine Society Guidelines.\n2. Male and female patients older than 21 years.\n3. Willingness to participate and ability to provide informed consent.\n\nExclusion Criteria:\n\n1. Patients with exclusion criteria for the MRI, such as:\n\n   * implanted devices (surgical clips, heart pacemakers or defibrillators, cochlear implants)\n   * iron-based tattoos\n   * any other pieces of metal or devices that are not MR-Safe anywhere in the body\n   * patients who exhibit noticeable anxiety and\u002For claustrophobia into the MRI scanner\n   * pregnancy\n2. Diagnosis of heart failure NYHA classes III and IV\n3. Impaired renal function with eGFR\\\u003C30 ml\u002Fmin or proteinuria \\> 1 g\u002F24h\n4. Liver disease with cirrhosis (Child-Pugh class C) or hypoalbuminemia\n5. Muscular dystrophies\n6. Patients with active cancer or severe comorbid conditions likely to compromise survival or study participation\n7. Unwillingness or other inability to cooperate","21 Years",{"count":530,"type":21},80,"The study aims to provide quantitative facts on the pathophysiological changes in tissue Na+ content during Na+\u002FK+ redistribution disorders in patients with PA in response to standard therapy. The investigators hypothesize that patients with primary aldosteronism have excessive Na+ storage in the muscle, which can now be quantified non-invasively using 23NaMRI. In analogy to the role of HbA1c as a metabolic long-term marker in diabetes, the quantifiable changes in muscle Na+ content may deliver the data evidence necessary to justify and conduct randomized diagnostic endpoint outcome trials in the future, with the ultimate aim to improve PA detection rate and treatment.",[225,27,533],"Hypokalemia",[535,536,537],"NaMRI","muscle Na+ quantification","K+ supplementation","2025-06-04",{"date":540,"type":35},"2025-06-06",{"date":542,"type":35},"2023-12-27",{"date":544,"type":21},"2026-08-31",{"name":546,"class":42},"Jens Titze",4,{"id":549,"slug":550,"hasResults":12,"nctId":551,"briefTitle":552,"officialTitle":552,"acronym":4,"eligibilityCriteria":553,"healthyVolunteers":98,"sex":18,"minAge":51,"maxAge":4,"enrollmentInfo":554,"targetDuration":4,"studyType":22,"phases":556,"briefSummary":557,"conditions":558,"keywords":560,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":567,"lastUpdatePostDateStruct":568,"startDateStruct":570,"completionDateStruct":572,"leadSponsor":574,"locationsCount":43},"100591463","continuous-steroid-monitoring-in-interstitial-fluid-with-wearable-and-nanoparticle-enhanced-biosensors-for-improved-management-of-adrenal-disorders-100591463","NCT06980753","Continuous Steroid Monitoring in Interstitial Fluid With Wearable and Nanoparticle-enhanced Biosensors for Improved Management of Adrenal Disorders","Inclusion Criteria:\n\n* Individuals (males and females) older than 18 years;\n* Patients with primary adrenal insuffiency (cortisol and aldosterone deficiency);\n* Patients with Cushing Syndrome (cortisol excess)\n* Patients with Primary Aldosteronism (aldosterone excess)\n\nExclusion Criteria:\n\n* Use of estrogen-containing oral contraceptive medication within the past 6 weeks;\n* Pregnancy or lactation;\n* Use of oral, inhaled, parenteral, or topical glucocorticoids within the past 30 days.",{"count":555,"type":21},246,[24],"The goal of this project is to provide novel technology that will pave the way from the present single-point (analogue) endocrinology towards continuous cortisol and aldosterone monitoring with full time resolution. Current endocrine practice relies on occasional and often random determination of hormone level or functional tests that require a clinical setting. These measurements include sample extraction and analysis in a clinical laboratory rendering such tests laborious and expensive. Most importantly, through the individual variations of hormone oscillation and spatiotemporal distribution of hormones, infrequent hormone measurements have limited diagnostic and prognostic value as the dynamic changes are not captured and relevant intra-individual variability occurs. A requirement for this vision are sensing solutions capable to track hormone dynamics over prolonged periods at high patient comfort (e.g., at home), as targeted by this research proposal. This project has the overarching goals of (1) establishing dynamic interstitial aldosterone and cortisol monitoring as reliable diagnostic tool for cortisol and aldosterone excess or deficiency, and (2) develop a wearable molecular sensing device to detect them accurately.",[559,27,203],"Cushing Syndrome",[561,562,563,564,565,566],"Aldosterone","Cortisol","Biossensor","Interstitial fluid","Adrenal insuficiency","Cushing syndrome","2025-05-16",{"date":569,"type":35},"2025-05-20",{"date":571,"type":21},"2025-06-01",{"date":573,"type":21},"2025-12-01",{"name":575,"class":42},"University of Sao Paulo General Hospital",{"id":577,"slug":578,"hasResults":12,"nctId":579,"briefTitle":580,"officialTitle":581,"acronym":4,"eligibilityCriteria":582,"healthyVolunteers":12,"sex":18,"minAge":51,"maxAge":583,"enrollmentInfo":584,"targetDuration":4,"studyType":22,"phases":586,"briefSummary":587,"conditions":588,"keywords":589,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":593,"lastUpdatePostDateStruct":594,"startDateStruct":595,"completionDateStruct":596,"leadSponsor":597,"locationsCount":43},"100477754","the-effect-of-saae-on-ventricular-remodeling-in-pa-patients-100477754","NCT05501080","The Effect of SAAE on Ventricular Remodeling in PA Patients","The Effect of Selective Adrenal Artery Embolization and Spironolactone on Ventricular Remodeling in Nondominant Lateral Secretory Primary Aldosteronism： A Randomized Controlled Clinical Study","Inclusion Criteria:\n\n* (1) Age 18-60 years old, regardless of gender;\n* (2) Blood pressure conditions meet one of the following: 1) Office blood pressure ≥ 140\u002F90mmHg; 2) Ambulatory blood pressure monitoring whole day blood pressure \\> 130\u002F80 mmHg or daytime blood pressure \\> 135\u002F85 mmHg;\n* (3) After strict drug elution, it met the diagnostic criteria of primary aldosteronism, and bilateral primary aldosteronism was confirmed by adrenal venous sampling;\n* (4) No surgical intent or contraindication to surgery and willing to undergo pharmacological treatment or percutaneous superselective adrenal artery embolization;\n* (5) The patient or his\u002Fher legal representative shall sign the written informed consent approved by the ethics committee before the screening.\n\nExclusion Criteria:\n\n* (1) Primary hypertension or secondary hypertension with other causes;\n* (2) A woman who is pregnant or lactating, or has a birth plan for the next year;\n* (3) There are serious organic diseases, especially liver and kidney dysfunction(eGFR\\\u003C45 mL\u002Fmin\u002F1.73 m2);\n* (4) Severe allergy to contrast medium;\n* (5) Other serious organic diseases, life expectancy \\\u003C 12 months;\n* (6) Adrenal CT showed adenoma.;\n* (7) Patients are enrolled or want to participate in other clinical studies. During the enrollment study, the results of this study will be affected.","60 Years",{"count":585,"type":21},112,[24],"The study aims to assess the effect of superselective adrenal arterial embolization on ventricular remodeling in primary aldosteronism without lateralized aldosterone secretion by comparing it with spironolactone therapy.",[27],[410,411,590,591,592],"bilateral primary aldosteronism","Nondominant Lateral Secretory Primary Aldosteronism","Ventricular Remodeling","2025-05-13",{"date":567,"type":35},{"date":299,"type":35},{"date":370,"type":21},{"name":421,"class":42},{"id":599,"slug":600,"hasResults":12,"nctId":601,"briefTitle":602,"officialTitle":603,"acronym":604,"eligibilityCriteria":605,"healthyVolunteers":12,"sex":18,"minAge":51,"maxAge":583,"enrollmentInfo":606,"targetDuration":4,"studyType":22,"phases":608,"briefSummary":609,"conditions":610,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":613,"lastUpdatePostDateStruct":614,"startDateStruct":615,"completionDateStruct":616,"leadSponsor":618,"locationsCount":43},"100555553","primary-aldosteronism-superselective-embolization-vs-laparoscopic-endocrine-curative-therapy-100555553","NCT06513585","Primary Aldosteronism: Superselective Embolization vs. Laparoscopic Endocrine Curative Therapy","The First Affiliated Hospital of Xinjiang Medical University","PA-SELECT","Inclusion Criteria:\n\n* Age 18-60\n* Diagnosed with primary aldosteronism according to the 2016 Clinical guidelines of the International Endocrine Society\n* Primary aldosteronism diagnosed according to international guidelines Unilateral disease by AVS or PET-CT criteria\n* Patients and their family members signed informed consent and agreed to participate in the study\n\nExclusion Criteria:\n\n* A history of severe hypersensitivity to contrast media\n* Severe liver disease complications, such as thrombocytopenia, esophageal varices rupture bleeding, etc\n* Renal insufficiency (serum creatinine \\> 176mmol\u002FL or estimated glomerular filtration rate \\\u003C min.1.73m2)\n* Combined with other secondary hypertension, such as pheochromocytoma, hypercortisolism, renal vascular hypertension (such as renal artery stenosis), renin secretory tumor, renal parenchymatous hypertension, drug-induced hypertension (such as long-term use of glucocorticoids, contraceptives, estrogen, herbal medicines containing glycyrrhizin), pregnancy hypertension and other secondary hypertension\n* Combined with genetic diseases: such as false aldosteronism (Liddle syndrome), Bartter syndrome, familial hypokalemia and hypomagnesia (Gitelman syndrome)\n* Stroke, myocardial infarction and stent implantation occurred in the past 3 months\n* Serious other diseases, such as heart dysfunction (grade IV), acute infections, autoimmune diseases, various malignant tumors, etc\n* Participated in other clinical trials within the past 3 months\n* Pregnant, breastfeeding, or planning a pregnancy\n* Identify patients with alcohol allergy",{"count":607,"type":21},570,[24],"The aim of this study was to compare the efficacy and safety of adrenalectomy and superselective adrenal artery embolization in a prospective, multicenter, randomized controlled study. To provide a new interventional alternative therapy for primary aldosteronism.",[27,611,612],"Suprarenalectomy","Super Selective Adrenal Artery Embolization","2025-04-14",{"date":233,"type":35},{"date":327,"type":35},{"date":617,"type":21},"2026-12-01",{"name":350,"class":42}]